GlassScriptPhysician profile
Tom Minas
NPI 1396839650
$2,468,412.86
in general payments reported to CMS, 2019-2025
24 companies · $240K in 2025
The $240K reported for 2025 was more than what 98% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $642K · 2020: $498K · 2021: $480K · 2022: $381K · 2023: $221K · 2024: $6,487 · 2025: $240K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $231K · Consulting Fee: $207K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $10K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,583 · Honoraria: $5,250 · Food and Beverage: $3,235 · Travel and Lodging: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $231,348.86 |
| Consulting Fee | $207,084.54 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $10,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,582.88 |
| Honoraria | $5,250.00 |
| Food and Beverage | $3,235.01 |
| Travel and Lodging | $1,072.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Conformis, INC. | $2,118,331.08 | 2019-2023 | Itotal Identity Cruciate Retaining Knee Replacement System, Identity Imprint Knee Replacement System |
| Restor3d, INC. | $232,078.14 | 2023-2025 | |
| Vericel Corporation | $115,358.49 | 2019-2025 | Maci |
| Joint Restoration Foundation, INC. | $778.34 | 2019 | |
| Smith+Nephew, INC. | $734.12 | 2019-2025 | Evos, N/A, Smart Tsf |
| Aesculap Biologics, LLC | $433.41 | 2019-2023 | Novocart 3d |
| Episurf Medical, INC. | $138.83 | 2024 | |
| Pacira Therapeutics, INC. | $84.45 | 2019 | |
| Nuvasive Specialized Orthopedics, INC. | $64.41 | 2019 | |
| Axogen | $45.57 | 2019 | |
| Bioventus LLC | $45.43 | 2020-2025 | Durolane |
| Orthofix Medical, INC. | $40.93 | 2020-2021 | |
| Globus Medical, INC. | $37.89 | 2025 | Anthem |
| Stryker Corporation | $33.35 | 2023 | T2 Alpha |
| Ethicon US, LLC | $29.45 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $26.53 | 2025 | Vykat Xr |
| Biotissue Holdings INC. | $25.40 | 2025 | |
| Kerecis Limited | $22.97 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide, Kerecis Omega3 Marigen |
| Acera Surgical, INC. | $21.23 | 2022 | |
| Solventum Corporation | $20.69 | 2025 | Prevena |
| Kowa Pharmaceuticals America, INC. | $17.77 | 2022 | |
| Kci USA, INC. | $17.63 | 2023 | Prevena |
| Heraeus Medical, LLC. | $14.34 | 2022 | |
| Cumberland Pharmaceuticals, INC. | $12.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tom Minas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.